In its latest Form 13F filing, Alpha Cubed Investments LLC more than tripled its holding in UnitedHealth Group, acquiring an additional 89,105 shares during the third quarter for a total position of 124,682 shares. This stake, valued at approximately $43.05 million at quarter end, now represents 1.5% of Alpha Cubed’s overall portfolio and ranks as its 18th largest position. The dramatic 250.5% increase underscores growing conviction among active managers in UnitedHealth’s long-term prospects, particularly as the stock remains heavily held by institutional investors (87.86% ownership by hedge funds and other institutions).

Several major brokerages have recently reviewed their outlook on UnitedHealth. Zacks Research moved its recommendation from Strong Sell to Hold, while JPMorgan Chase raised its target price from $310 to $425 and maintained an Overweight rating. Piper Sandler and KeyCorp both reiterated Overweight stances, and Morgan Stanley trimmed its target modestly from $411 to $409, preserving its Overweight view. Of the 29 analysts covering the company, one assigns a Strong Buy, 17 recommend Buy, nine issue Hold and two advise Sell. The consensus target price stands at $380.67, reflecting broad confidence in steady earnings growth.

UnitedHealth reported fourth-quarter adjusted earnings per share of $2.11, narrowly topping the consensus by $0.02, while revenue rose 12.3% year-over-year to $113.22 billion, slightly missing estimates. The company delivered a 14.79% return on equity and a 2.69% net margin for the period. Management set full-year 2026 adjusted EPS guidance at approximately $17.75, in line with analyst expectations, and projected revenue above $439 billion. With operating leverage initiatives underway—particularly in its Optum services unit—UnitedHealth aims to sustain margin expansion despite a challenging reimbursement environment.

UnitedHealth continued its track record of shareholder returns by declaring a quarterly dividend of $2.21 per share, translating into an annualized payout of $8.84 and a yield near 3.0%. The ex-dividend date was December 8, with the payment made December 16. The company’s payout ratio stands at 67.02%, reflecting a balanced approach between returning capital and funding growth investments. Liquidity metrics are solid, with a current ratio of 0.79 and a quick ratio of 0.82, while the debt-to-equity ratio of 0.72 underscores prudent leverage management across its diversified healthcare platform.